Moreover, the results shared in this publication support the relevance of exploring small molecule GCase modulators as a promising potential disease-modifying treatment option for aging, Alzheimer’s disease or other tauopathies beyond those directly associated with GBA1 mutations. This evidence concerns the gene GBA1 and tauopathy.